Journal
EUROPEAN NEUROPSYCHOPHARMACOLOGY
Volume 16, Issue 7, Pages 498-503Publisher
ELSEVIER
DOI: 10.1016/j.euroneuro.2005.12.004
Keywords
serotonin 1A receptor; polymorphism; fluoxetine; pharmacogenetics; selective serotonin reuptake inhibitor
Ask authors/readers for more resources
The firing rate of dorsal raphe serotonergic neurons is modulated by somatodendritic 5-hydroxytryptamine 1A (HTR1A) autoreceptors. Evidence from animal and clinical studies has suggested that desensitization of HTR1A is implicated in the antidepressant therapeutic mechanism of selective serotonin reuptake inhibitors (SSRIs). Recent studies, including our recent findings, have reported that a functional HTR1A C-10196 polymorphism in the promoter region, as well as a nonsynonymous polymorphism, Gly272Asp, may be associated with SSRI pharmacogenetics. In this study, we tested whether Gly272Asp genetic variants are related to a 4-week fluoxetine antidepressant effect in 222 Chinese major depressive patients. We also tested the linkage disequilibrium (LD) measurement between HTR1A Gly272Asp and C-10196 polymorphisms, and haplotype analysis was conducted to assess the association between the two markers within the HTR1A gene and fluoxetine antidepressant response. The results show that the HTR1A Gly272Asp polymorphism was not associated with fluoxetine therapeutic response. The two markers are in strong LD and the HTR1A haplotype of the two polymorphisms is associated with fluoxetine therapeutic response. This association is gender-specific and mostly arises from the effect of HTR1A C-10196 polymorphism: female patients with -1019C/C genotype showed a better response than 1019G carriers. These findings need to be confirmed in other ethnic populations. (c) 2005 Elsevier B.V. and ECNP. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available